红细胞生成素的临床研究进展

自１９８５年人促红细胞生成素（ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ，ＥＰＯ）基因及其ｃＤＮＡ被成功地克隆以来，利用基因工程大批量生产重组人促红细胞生成素（Ｈｕｍａｎ ｒｅ－ｃｏｍｂｉｎａｎｔ ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ， ｈｒＥＰＯ）并应用于临床治疗多种类型的贫血，ＥＰＯ的基础和应用研究方兴未艾，取得了令人瞩目的成就。１ＥＰＯ的生物学特性 人类ＥＰＯ基因位于７号染色体长臂２２区，ＥＰＯ分子量３４ｋＤ，按碳水化合物表达量的不同，将人类自然的 ＥＰＯ分为两种形式： ａ型含３１％碳水化合物，β型含 ２４％碳水化合…

Progress in study on clinical erythropoietin

Erythropoietin (EPO ) is the primary growth factor for the red cell lineage. Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anamia associated with chronic renal failure, cancer-related anemia, HIV infection, myelodysplasia, reheumatoid arthritis, matermal and neonatal anamia. Other uses of EPO under investigation are in perioperative surgery, autologous blood transfusion, bone marrow transplantation. All of above-mentioned which shown that rHuEPO increases hemoglobin and hematocrit levels and reduces the need for transfusions. Besides, EPO can be used as a marker of fetal anemia and fetal hypoxia. It's also used to diagnosis of polycythemia vera (PV ) by the serum erythropoietin level and endogenous erythroid colony assay which can distinguished PV relative polycythemia from secondary erythrocytosis. Recent clinical observasions show that EPO even plays a roll in regulation of endocrine abnormal. Up to now, EPO therapy seems to be a safer method for treatment the patients. The side effects included those due to direct administration of EPO and related to increased red cell mass, like flu-like symptoms, hypertensive, iron deficiency, rise in blood viscosity, clotting of dialyzer, hyperkalemia and hyperphosphatemia, which can be prevented by rational use of rHuEPO. Genetic therapy by use EPO-gene transfer is a promising method which will substitude the rHuEPO many times injected.